One-pill once-a-day HAART: A simplification strategy that improves adherence and quality of life of HIV-infected subjects

Patient Preference and Adherence

Volumn 4, Issue , 2010, Pages 115-125

  Airoldi, Monica ^a,f   Zaccarelli, Mauro ^b   Bisi, Luca ^c   Bini, Teresa ^d   Antinori, Andrea ^b   Mussini, Cristina ^c   Bai, Francesca ^d   Orofino, Giancarlo ^e   Sighinolfi, Laura ^g   Gori, Andrea ^f   Suter, Fredy ^a   Maggiolo, Franco ^a  

^a OSPEDALI RIUNITI   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d Ospedale San Paolo ^*  (Italy)

^e AMEDEO DI SAVOIA HOSPITAL   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

^g Ospedale Sant'Anna   (Italy)

Author keywords

Adherence; EFV FTC TDF; Once daily antiretroviral regimen; Patient preferences; QoL; Single pill regimen

Indexed keywords

EID: 77954618054     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;102:43-49.
2. Rodriguez-Rosado R, Jimenez-Nacher I, Soriano V, et al. Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS. 1998;12:1112-1113.
3. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17:1925-1932.
4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
5. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favour different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40:158-163.
6. Bangsberg D. Less than 95% adherence to nonnucleoside reverse transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-941.
7. Shah B, Walshe L, Saple DG, et al. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis. 2007;44:1235-1244.
8. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI-or PI-treated patients. HIV Clin Trials. 2007;8:282-292.
9. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationship for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223-231.
10. Bangsberg DR, Porco TC, Kagay C, et al. Modelling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis. 2004;190:162-165.
11. Kleeberger CA, Phair JP, Strathdee SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82-92.
12. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psycological variables influencing adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 1999;13:1763-1769.
13. Vervoort SCJM, Borleffs JCC, Hoepelman AIM, et al. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21:271-281.
14. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV infected patients. HIV Clin Trials. 2002;5:371-378.
15. Trotta MP, Ammassari A, Cozzi-Lepri A, et al. Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than those receiving protease inhibitor-containing regimens. AIDS. 2003;17: 1099-1102.
16. Flandre P, Peytavin G, Meifreddy V, et al. Adherence to antiretroviral therapy and outcomes in HIV infected patients enrolled in an induction/ maintenance randomized trial. Antivir Ther. 2002;7:113-121.
17. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity of HIV-infected patients on antiretroviral therapy. Self-report of the relative importance of multiple attributes of Highly Active Antiretroviral Therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36:808-816.
18. Boyle B, Jayaweera D, Witt MD, et al. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials. 2008;9:164-176.
19. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824-830.
20. Holmes WC, Bilker WB, Wang H, et al. HIV/AIDS-specific quality of life and adherence to antiretroviral therapy over time. J Acquir Immune Defic Syndr. 2007;46:323-327.
21. Benson CA, van der Horst C, LaMarca A, et al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS. 2004;18:2269-2276.
22. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36) Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-263.
23. Sriwatanakul K, Kelvie W, Lasagna L, et al. Studies with different types of visual analogue scales for measurement of pain. Clin Pharmacol Ther. 1983;34:234-239.
24. Giordano TP, Guzman D, Clark R, et al. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5:74-79.
25. Clotet B, Carmena J, Pulido F, et al. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. HIV Clin Trials. 2004; 5:33-39.
26. Centers for Disease Control and Prevention. 1993 revised system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:9-12.
27. Glass TR, De Geest S, Weber R, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients. The Swiss HIV Cohort study. J Acquir Immune Defic Syndr. 2006;41:385-392.
28. Hays RD, Woolley JM. The concept of clinically meaningful in healthrelated quality-of-life research. How meaningful is it? Pharmacoeconomics. 2000;18:419-423.
29. Bisson GP, Rowh A, Weinstein R, et al. Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr. 2008;49:107-110.
30. Golin CE, Earp J, Tien HC, et al. A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. J Acquir Immune Defic Syndr. 2006;42:42-51.
31. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-449.
32. Heath KV, Singer J, O'Shaughnessy MV, et al. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:211-217.
33. Mannheimer SB, Wold N, Gardner EM, et al. Mild-to moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals. Clin Infect Dis. 2008;46:941-945.
34. Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008;14:762-766.
35. DeJesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51:163-174.
36. Holmes WC, Bilker WB, Wang H, et al. HIV/AIDS-specific quality of life and adherence to antiretroviral therapy over time. J Acquir Immune Defic Syndr. 2007;46:323-327.